Loading...
XNASSCYX
Market cap37mUSD
Dec 24, Last price  
0.99USD
1D
-2.94%
1Q
-34.44%
Jan 2017
-68.97%
IPO
-88.76%
Name

SCYNEXIS Inc

Chart & Performance

D1W1MN
XNAS:SCYX chart
P/E
0.56
P/S
0.27
EPS
1.77
Div Yield, %
0.00%
Shrs. gr., 5y
61.62%
Rev. gr., 5y
252.64%
Revenues
140m
+2,652.72%
16,837,00016,857,0001,256,000257,000257,000257,000257,000121,000013,163,0005,091,000140,141,000
Net income
67m
P
-11,477,000-30,461,000-4,234,000-32,623,000-29,989,000-25,060,000-12,468,000-55,234,000-55,185,000-32,866,000-62,809,00067,041,000
CFO
60m
P
-10,596,000-4,307,000-9,472,000-24,545,000-29,353,000-24,556,000-28,323,000-38,119,000-49,354,000-54,560,000-79,883,00060,159,000
Earnings
Mar 26, 2025

Profile

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
URL
https://www.scynexis.com/
IPO date
May 02, 2014
Employees
36
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
140,141
2,652.72%
5,091
-61.32%
13,163
 
Cost of revenue
46,552
27,887
24,085
Unusual Expense (Income)
NOPBT
93,589
(22,796)
(10,922)
NOPBT Margin
66.78%
Operating Taxes
138
(4,700)
(3,088)
Tax Rate
0.15%
NOPAT
93,451
(18,096)
(7,834)
Net income
67,041
-206.74%
(62,809)
91.11%
(32,866)
-40.44%
Dividends
Dividend yield
Proceeds from repurchase of equity
18
47,248
38,556
BB yield
-0.02%
-71.07%
-23.96%
Debt
Debt current
680
282
70
Long-term debt
17,661
51,518
46,830
Deferred revenue
2,727
Other long-term liabilities
21,680
18,644
21,407
Net debt
(79,615)
(21,866)
(57,802)
Cash flow
Cash from operating activities
60,159
(79,883)
(54,560)
CAPEX
(9)
(1,172)
Cash from investing activities
(34,877)
(27,389)
(1,172)
Cash from financing activities
(36,721)
48,602
67,120
FCF
81,550
(17,776)
(7,451)
Balance
Cash
74,362
73,503
104,484
Long term investments
23,594
163
218
Excess cash
90,949
73,411
104,044
Stockholders' equity
(355,207)
(422,252)
(359,447)
Invested Capital
467,996
492,726
465,738
ROIC
19.45%
ROCE
82.98%
EV
Common stock shares outstanding
48,391
42,614
26,385
Price
2.23
42.95%
1.56
-74.43%
6.10
-20.26%
Market cap
107,911
62.33%
66,477
-58.70%
160,947
96.25%
EV
28,296
44,611
103,145
EBITDA
94,169
(22,190)
(10,543)
EV/EBITDA
0.30
Interest
3,130
5,198
2,660
Interest/NOPBT
3.34%